Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET)

Recovery of Function Clinical Trial

— BestBet  

Official title:

Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03635411
• Other study ID #: 829947
• Status: Recruiting
• Phase: Phase 1
• Start date: December 6, 2018
• Est. completion date: December 2020

Study information

• Verified date: January 2020
• Source: Elysium Health
• Contact: Carrie Sims
• Phone: 215-662-8819
• Email: carrie.sims[@]uphs.upenn.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET) A phase I, randomized, double-blind, placebo-controlled, single institutional pilot trial investigating the impact of nicotinamide riboside/pterstilbene (BasisTM) on functional recovery after traumatic fall in elderly patients

.

Description:

This Phase I pilot study will determine if supplementing with the combination of NR and Pter (BasisTM) is well tolerated and will provide the pretrial data necessary to plan a randomized clinical trial aimed at determining if BasisTM improves the functional outcome of injured elderly patients.

Primary Objective

• To determine if BasisTM is well tolerated by elderly patients up to 90 days post injury

Secondary Objectives:

• To determine if BasisTM preserves or improves muscular strength, endurance, and activity following traumatic injury in elders.

• To determine if BasisTM preserves or improves physiologic composition (muscle/fat ratio) following traumatic injury in elders.

• To determine if BasisTM decreases 90 day incidence of recurrent falls

• To determine the impact of BasisTM on subjective well-being (pain) and quality of life (EQ-5D-5L)

• To determine if BasisTM alters NAD and sirtuin activity in inflammatory cells.

Elderly trauma patients who present after a traumatic injury will be screened and enrolled within 48 hours of their trauma evaluation. Baseline status will be determined using functional surveys, physical assessments, and physiologic measurements. Patients will be randomized to either BasisTM or placebo for 90 days. Patients will be reassessed at 2 weeks, 6 weeks (optional) and 90 days. Activity and heart rate will be monitored continuously using a wrist FitBit Device.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: December 2020
• Est. primary completion date: November 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

1. = 65 year old

2. Patient presenting to trauma bay

Exclusion Criteria:

1. Currently taking medication for severe to moderate dementia (see Appendix 9)

2. Currently taking niacin, nicotinic acid, nicotinamide, or nicotinamide riboside

3. Pre-existing immobility (wheel chair or bed bound)

4. Renal failure requiring hemodialysis or peritoneal dialysis

5. End-stage Liver Disease (Model for End Stage Liver Disease Score = 25) (see Appendix 11)

6. Intubated prior to enrollment (excluding intubation for surgery)

7. More than 48 hours post-injury

8. Thoracic Anatomic Injury Score > 3 (see Appendix 10)

9. Other Injuries with Anatomic Injury Score >2, excluding thorax (see Appendix 10)

10. Hip fractures

11. Non-English speaking

Related Conditions & MeSH terms

• Recovery of Function

Intervention

Dietary Supplement:
• Nicotinamide Riboside and Pterostilbene
Nicotinamide riboside and pterostilbene manufactured by Basis
• Placebo
Sugar pill manufactured to mimic Basis supplement.

Locations

Country	Name	City	State
United States	Penn Presbyterian Medical Center	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Elysium Health	University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complications	To analyze patient complications through daily adverse event monitoring and summarize adverse events for each arm	90 days
Secondary	Grip Strength Scores	To measure if BasisTM preserves or improves grip strength using Jamar hand dynamo-meter in non-dominant hand	90 days
Secondary	Inhalation Volume Measurements	To measure if BasisTM preserves or improves lung volume by measuring inhaled volumes using incentive spirometry	90 days
Secondary	6 Minute Timed Walk Test Scores	To measure if BasisTM preserves or improves 6 minute Timed Walk Test according to the AmericanThoracic Society Guidelines.	90 days
Secondary	Timed Get Up and Go Test Scores	To measure if BasisTM preserves or improves timed get up and go scores	90 days
Secondary	Measurement of Muscle/ Fat Ratio	To measure if BasisTM preserves or improves physiologic composition (muscle/fat) ratio) using bioelectric impedance	90 days
Secondary	Incidence of Adverse Events	To analyze if BasisTM decreases 90 day incidence of recurrent falls	90 days
Secondary	Incidence of Pain and Daily Pain Medication Dosage	To analyze the impact of BasisTM on subjective well-being pain through measurement of pain medication amounts and frequency.	90 days
Secondary	Analysis of Quality of Life Scores	To analyze the impact of BasisTM on subjective well-being through analysis of EuroQol 5 Dimensions-5 Levels (EQ-5D-5L) scores and EuroQol Visual Analogue Scale (EQ Vas). EQ-5D-5L Scores consist of 5 sections: Mobility, Self-Care, Usual Activities, Pain/ discomfort and Anxiety/ Depression. The minimum score in each is 1, and the maximum is 5, where 5 indicates extreme problems and 1 indicates no problems. A total of 3125 possible health states exist and each stats is referred to in terms of a 5 digit code. State 11111 indicates no problems on any of the 5 dimensions, whereas state 12345 indicates no problems with mobility, slight problems with washing or dressing, moderate problems with doing usual activities, severe pain or discomfort and extreme anxiety or depression. The EQ-VAS is scored from 0 to 100 where 0 means the worst health you can imagine and 100 means the best health you can imagine.	90 days
Secondary	Late Life Function and Disability Instrument Scores analysis as a measure of subject independence, function, and disability	To analyze the impact of BasisTM on subjective well-being through analysis of Late Life Function and Disability Scores. Questions are scored on a scale of 5 to 1, where 1 means no difficulties with function and 1 means patients are unable to complete the functions on their own. Disability questions are scored from 1 to 5, where 1 means subjects do not complete activities and feel limited and 5 means subjects can complete activities and don't feel at all limited. Scores are computed using the LLFDI Scoring Software.	90 days
Secondary	Analysis of scores on Mini Mental Status Exam as a measure of cognitive function and dementia	To analyze the impact of BasisTM on subjective well-being through analysis of Mini Mental Status Scores. The maximum score is 30 and the sections are orientation (10 points), registration (3 points), attention and calculation (5 points), recall (3 points), language and praxis (9 points). 0 is the lowest and 30 is the best score.	90 days
Secondary	Analysis of subject nutrition through Mini Nutritional Assessment Scores	To analyze the impact of BasisTM on subjective well-being through analysis of Mini Nutritional Assessment scores. The maximum score is 14 points and the lowest (worst score) is 0.	90 days
Secondary	Analysis of Subject independence using Barthel Index scores	To analyze the impact of BasisTM on subjective well-being through analysis of Barthel Index Scores. The index consists of 10 Activities of daily living, 8 of which represent activities related to personal care while 2 are related to mobility. The index yields a total score out of 100 with higher scores indicating greater degrees of functional independence.	90 days
Secondary	Analysis of patient comorbidities as a measure of adverse events in evaluating Basis tolerability	To analyze the impact of BasisTM on subjective well-being through analysis of Charlson comorbidity index scores. The CCI accounts for 19 pre-defined comorbid conditions and is given a different weight depending on each's association with 1-year mortality. The total score in CCI is determined by the combined weight of the patient's conditions, where higher scores represent worse conditions.	90 days
Secondary	Analysis of inflammatory cell activity	To measure if BasisTM alters Nicotinamide adenine dinucleotide (NAD) and sirtuin activity in inflammatory cells. Liquid chromatography mass spectrometry will assay for NAD.	90 days
Secondary	Analysis of Mitochondrial Function	Mitochondrial content will be determined by citrate synthase activity. Mitochondrial respiration and the generation of reactive oxygen species will be measured using high-resolution respirometry and fluoremtry.	90 days